Shares of WUXI APPTEC Co., Ltd (02359.HK) soared 16.21% on Thursday amid reports that the Chinese biotech firm and its related companies are exploring the divestment of certain assets in response to potential U.S. restrictions.
According to a Financial Times report, WUXI APPTEC is considering selling its WUXI Advanced Therapies unit, which manufactures cell and gene therapies and has operations in the United States. The report, citing sources familiar with the matter, also indicated that WUXI Biologics is gauging interest in its European production facilities.
The reported asset sale plans come as the U.S. House of Representatives recently passed a draft of the Biosecure Act, which designates the WUXI companies as "biotechnology companies of concern" due to alleged military ties. If enacted, the legislation could bar U.S. government agencies from using funding or making contracts that involve certain biotechnology equipment or services from designated companies like WUXI.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.